Related references
Note: Only part of the references are listed.Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
Francois Quenet et al.
LANCET ONCOLOGY (2021)
Effective Strategies to Predict Survival of Colorectal Peritoneal Metastases Patients Eligible for Cytoreductive Surgery and HIPEC
Geert A. Simkens et al.
CANCER MANAGEMENT AND RESEARCH (2021)
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
Marta Schirripa et al.
CLINICAL COLORECTAL CANCER (2020)
RAS Mutation Decreases Overall Survival After Optimal Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy of Colorectal Peritoneal Metastasis: A Modification Proposal of the Peritoneal Surface Disease Severity Score
A. Arjona-Sanchez et al.
ANNALS OF SURGICAL ONCOLOGY (2019)
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parralel-group, phase II-III, randomised, superiority study (CAIRO6)
Koen P. Rovers et al.
BMC CANCER (2019)
Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods
J. Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy
S. Hallam et al.
BJS OPEN (2019)
Mutations of RAS/RAF Proto-oncogenes Impair Survival After Cytoreductive Surgery and HIPEC for Peritoneal Metastasis of Colorectal Origin
Marcel Andre Schneider et al.
ANNALS OF SURGERY (2018)
Perioperative systemic therapy for resectable colorectal peritoneal metastases: Sufficient evidence for its widespread use? A critical systematic review
Koen P. Rovers et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
The Role of Neoadjuvant and Adjuvant Systemic Chemotherapy with Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Systematic Review
Kathryn Waite et al.
ANNALS OF SURGICAL ONCOLOGY (2017)
Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
R. A. Devilee et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Development of a Prognostic Nomogram for Patients with Peritoneally Metastasized Colorectal Cancer Treated with Cytoreductive Surgery and HIPEC
Geert A. Simkens et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Carmen J. Allegra et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database
Jan Franko et al.
LANCET ONCOLOGY (2016)
Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer: A Population-Based Study
P. Quere et al.
DISEASES OF THE COLON & RECTUM (2015)
Neoadjuvant Chemotherapy with Bevacizumab May Improve Outcome after Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Colorectal Carcinomatosis
Wim Ceelen et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
The American Society of Peritoneal Surface Malignancies (ASPSM) Multiinstitution Evaluation of the Peritoneal Surface Disease Severity Score (PSDSS) in 1,013 Patients with Colorectal Cancer with Peritoneal Carcinomatosis
Jesus Esquivel et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Comparison of Prognostic Scores for Patients with Colorectal Cancer Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Peter H. Cashin et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Patient Selection for Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis Using Serum Tumor Markers An Observational Cohort Study
Peter H. Cashin et al.
ANNALS OF SURGERY (2012)
Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Wendy De Roock et al.
LANCET ONCOLOGY (2011)
KRAS Status in Patients With Colorectal Cancer Peritoneal Carcinomatosis and Its Impact on Outcome
Suzanne M. Gillern et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Impact of the Peritoneal Surface Disease Severity Score on Survival in Patients with Colorectal Cancer Peritoneal Carcinomatosis Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
KRAS and BRAF Mutational Status in Primary Colorectal Tumors and Related Metastatic Sites: Biological and Clinical Implications
Antoine Italiano et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Complete Cytoreductive Surgery Plus Intraperitoneal Chemohyperthermia With Oxaliplatin for Peritoneal Carcinomatosis of Colorectal Origin
Dominique Elias et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy
VJ Verwaal et al.
BRITISH JOURNAL OF SURGERY (2004)
Peritoneal carcinomatosis from colorectal cancer
DG Jayne et al.
BRITISH JOURNAL OF SURGERY (2002)
Share Paper
